Chism J P, Rickert D E
Department of Drug Metabolism, Glaxo Research Institute.
Drug Metab Dispos. 1996 Jan;24(1):34-40.
Remifentanil is a mu opioid receptor agonist, structurally related to fentanyl, being developed for use in anesthesia. Remifentanil was designed to be cleared rapidly by ester hydrolysis. To determine the pharmacokinetics of remifentanil in conscious beagle dogs, venous blood was collected at various times during and after the end of a 25 min intravenous infusion of the compound (0.36 or 36.0 micrograms [free base]/kg/min). In a separate set of studies designed to measure tissue clearance of remifentanil, catheters were implanted in various blood vessels of anesthetized beagle dogs to sample blood entering and leaving selected tissues. Approximately 40 min (steady state achieved) after initiation of remifentanil infusions at the same rates as described above, and while infusions were still in progress, blood was collected from the series of catheters. In a third set of experiments, blood obtained from either untreated dogs or from a dog that had been anesthetized, was incubated with remifentanil (either 10 or 1000 ng (free base)/ml). The observed half-life was used to provide an estimate of in vivo blood metabolic clearance of the compound. Extracts of the blood from all experiments were analyzed by either an HPLC or mass spectrometry assay for remifentanil concentration. There were no differences in systemic clearance (approximately 45 ml/kg/min), volume of distribution at steady state, mean residence time, dose-normalized normalized concentration at steady state, or dose-normalized AUC between the doses administered to conscious dogs; the t1/2 alpha was 3-5 min. In the anesthetized animals, muscle and intestine had the highest tissue clearance rates, but liver, kidneys, and blood each accounted for 1% or less of systemic clearance. The results indicate that, within the range of doses studied, the pharmacokinetics of remifentanil during infusion to steady state in dogs were not dependent on dose, and that the liver contributed very minimally to the overall clearance of the compound.
瑞芬太尼是一种μ阿片受体激动剂,在结构上与芬太尼相关,正被开发用于麻醉。瑞芬太尼设计为通过酯水解快速清除。为了确定瑞芬太尼在清醒比格犬体内的药代动力学,在静脉输注该化合物(0.36或36.0微克[游离碱]/千克/分钟)25分钟期间及结束后的不同时间采集静脉血。在另一组旨在测量瑞芬太尼组织清除率的研究中,将导管植入麻醉比格犬的各种血管中,以采集进入和离开选定组织的血液样本。以与上述相同的速率开始输注瑞芬太尼后约40分钟(达到稳态),且输注仍在进行时,从一系列导管采集血液。在第三组实验中,将从未经处理的犬或已麻醉的犬采集的血液与瑞芬太尼(10或1000纳克[游离碱]/毫升)一起孵育。观察到的半衰期用于估计该化合物在体内血液中的代谢清除率。通过高效液相色谱法或质谱分析法对所有实验的血液提取物进行分析,以测定瑞芬太尼浓度。给予清醒犬的不同剂量之间,全身清除率(约45毫升/千克/分钟)、稳态分布容积、平均驻留时间、稳态剂量归一化浓度或剂量归一化曲线下面积均无差异;α半衰期为3 - 5分钟。在麻醉动物中,肌肉和肠道的组织清除率最高,但肝脏、肾脏和血液各自占全身清除率的1%或更少。结果表明,在所研究的剂量范围内,犬在输注至稳态期间瑞芬太尼的药代动力学不依赖于剂量,且肝脏对该化合物总体清除的贡献非常小。